Selected article for: "causative agent and cellular infection"

Author: Jones, Georgia Wilson; Monopoli, Marco P; Campagnolo, Luisa; Pietroiusti, Antonio; Tran, Lang; Fadeel, Bengt
Title: No small matter: a perspective on nanotechnology-enabled solutions to fight COVID-19
  • Cord-id: tuef8pnd
  • Document date: 2020_9_2
  • ID: tuef8pnd
    Snippet: There is an urgent need for safe and effective approaches to combat COVID-19. Here, we asked whether lessons learned from nanotoxicology and nanomedicine could shed light on the current pandemic. SARS-CoV-2, the causative agent, may trigger a mild, self-limiting disease with respiratory symptoms, but patients may also succumb to a life-threatening systemic disease. The host response to the virus is equally complex and studies are now beginning to unravel the immunological correlates of COVID-19.
    Document: There is an urgent need for safe and effective approaches to combat COVID-19. Here, we asked whether lessons learned from nanotoxicology and nanomedicine could shed light on the current pandemic. SARS-CoV-2, the causative agent, may trigger a mild, self-limiting disease with respiratory symptoms, but patients may also succumb to a life-threatening systemic disease. The host response to the virus is equally complex and studies are now beginning to unravel the immunological correlates of COVID-19. Nanotechnology can be applied for the delivery of antiviral drugs or other repurposed drugs. Moreover, recent work has shown that synthetic nanoparticles wrapped with host-derived cellular membranes may prevent virus infection. We posit that nanoparticles decorated with ACE2, the receptor for SARS-CoV-2, could be exploited as decoys to intercept the virus before it infects cells in the respiratory tract. However, close attention should be paid to biocompatibility before such nano-decoys are deployed in the clinic.

    Search related documents:
    Co phrase search for related documents
    • abo blood group system potential involvement and acute respiratory syndrome: 1, 2
    • acceptable safety profile and acute coronavirus infection: 1
    • acceptable safety profile and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • actual receptor and acute respiratory syndrome: 1
    • acute coronavirus infection and additional receptor: 1
    • acute coronavirus infection and local inflammation: 1, 2, 3
    • acute respiratory syndrome and additional receptor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • acute respiratory syndrome and adjuvant delivery: 1, 2, 3, 4
    • acute respiratory syndrome and admission patient present: 1, 2, 3
    • acute respiratory syndrome and live macrophage: 1
    • acute respiratory syndrome and local delivery: 1, 2, 3, 4, 5, 6, 7
    • adjuvant delivery and local delivery: 1